港股異動 | 石藥集團(1093.HK)漲近4%創階段新高 首季純利升26.9%至14.72億
格隆匯5月24日丨石藥集團(1093.HK)午後開盤拉昇漲3.88%,報11.5港元創2018年7月以來新高價,總市值達1370億港元。石藥集團午間公佈,截至2021年3月31日止3個月,集團實現收入總額67.34億元人民幣(單位下同),同比增長9.9%;股東應占溢利14.72億元,同比增長26.9%。其中,抗腫瘤產品錄得銷售收入18.69億元,同比增加20.4%。未來三年,集團預計將上市新產品60餘個,其中預計市場空間超過10億元的重磅品種將不少於15個,而納米技術平台研發的米託蒽醌脂質體等產品,都是具有全球專利及極具市場價值的重磅產品。這些產品的上市必將強力支撐集團未來的高質量增長。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.